CÆLUM-CAPITAL
Cælum Capital Limited, a specialist investor focused on premium beverage businesses, announced the acquisition of a majority stake in Compass Box Delicious Whisky Limited, a London-based premium Scotch whisky brand. Compass Box is ranked 4th in the “Top Trending Brands” in Scotch whisky segment by Drinks International.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220505005290/en/
Cælum was set up by Manish Rungta, an ex-Diageo executive with a background in private equity. Cælum has brought in Maurice Doyle as the new CEO of Compass Box to partner with the Founder, John Glaser, in the continued development of the business. A spirits industry veteran, Maurice Doyle brings nearly 30 years of marketing, commercial, and executive leadership experience from within the global alcoholic beverages sector. “I am delighted to be joining Compass Box. It is a brand that I have long admired as a pioneer within Scotch whisky. I have a huge amount of respect for John and what he has achieved,” says Doyle.
Founded in London in 2000, Compass Box is a reflection of Glaser’s personal vision for what the future of whisky making should be. John Glaser was named by Whisky Advocate as one of the “Thirty Innovators Who Shaped Today’s Whisky” and one of the only Two alive today. “With Maurice joining me at the helm, we are excited to double-down on our determination to democratise the enjoyment of Scotch whisky, to continue releasing products that reveal the creative art behind blending,” says Glaser, who has described the Compass Box mission as, “fighting…what I call the ‘single malt hegemony.’”
Cælum investment will be used to strengthen the balance sheet of the Company, acquire inventory, and build production facilities. Cælum will help facilitate the ambition of Compass Box to provide more opportunities to explore, experiment and innovate, with curiosity and creativity as its guiding principles. Manish Rungta, the Managing Partner at Cælum said, “We are excited to partner with Compass Box and it is representative of the innovative and pioneering brands within the beverage category that we would like to invest behind.”
Metric Point Capital, acted as the exclusive financial advisor and placement agent to Cælum. “We are thankful for the support of the Metric Point team during a very complex process and a crowded North American fundraising market. Metric Point brought highly technical skillsets and a tailored solution for this unique proprietary deal and we ended up being oversubscribed in our fundraising,” said Manish Rungta.
Corporate Partner Tom Braiden led the team at Brown Rudnick, an international law firm, which acted as exclusive legal advisor to Cælum.
Cælum Capital Limited
Cælum Capital Limited is based in London and is a specialist investor focused on investing in premium beverage businesses based in North America and Europe with a focus on alcoholic beverages. Cælum was founded by Manish Rungta, who is the Managing Partner of the firm and has extensive investment experience in the beverage sector, both alcoholic and non-alcoholic. Ex-SABMiller executive Mark Eames has joined Cælum as an Operating Partner and has extensive strategic, operational, and financial planning experience within the beverage sector. Cælum targets opportunities in the beverage segment with investment amounts ranging from US$50 – 200 million. For more information, please visit www.caelumcap.co.uk
.
Compass Box
Compass Box are Scotch whiskymakers. The word ‘whiskymaker’ is their word – it does not appear in a dictionary. For over 20 years they have been relentlessly focused on reinventing Scotch whisky, with every new blend designed to help make the world of whisky a more interesting place. Compass Box have won more awards for innovation than any other producer in Scotland because they are always experimenting. Always looking for sparks of creativity that will deliver something totally compelling, yet completely surprising. This vision motivates them as whiskymakers. Their blends are consistently rated equal to or better than the great single malts of Scotland by the most respected voices in the industry. For more information, please visit www.compassboxwhisky.com
or @CompassBoxWhiskyCo
on Instagram.
Metric Point Capital
(Member FINRA and SIPC)
Metric Point Capital is a boutique private capital advisory firm specializing in raising institutional capital for alternative investment managers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005290/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MSCI Announces Baer Pettit to Retire as President17.11.2025 13:00:00 CET | Press release
Additional senior leadership changes will drive growth in new client segments and products MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leadership roles, including heading Client Coverage, Marketing and Index. He was appointed COO in 2015 and President in 2017, overseeing all products and operations, and he joined the Board of Directors in 2023. “Baer has been my longtime business partner, and he has played a pivotal role in shaping MSCI’s st
AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth17.11.2025 13:00:00 CET | Press release
Dr Lee is a seasoned biopharmaceutical executive with a proven track record of leading cross-functional teams to successfully develop and commercialize innovative therapies in oncology AdvanCell Pty Ltd (“AdvanCell”), a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Philina Lee, PhD as Chief Executive Officer and member of the Board of Directors. Dr Lee will head AdvanCell’s US expansion, accelerating clinical, manufacturing, and partnership activities to advance lead clinical candidate 212Pb-ADVC001 and the company’s innovative radiopharmaceutical portfolio. She will assume her role from January 1, 2026, and will be based at the company’s new US headquarters near Boston/Cambridge, MA. “Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, C
Connections, Local Flavors, and Luxurious Experiences Top the 2026 Bacardi Cocktail Trends Report17.11.2025 13:00:00 CET | Press release
This year’s findings highlight a move towards more meaningful occasions, micro-indulgence, and storytelling cocktail experiences The five defining trends set to reshape cocktail culture and the spirits industry in 2026 are highlighted in the seventh annual Bacardi Cocktail Trends Report. The Report released by Bacardi Limited, the largest privately held international spirits company, in partnership with The Future Laboratory (TFL), draws on data from Bacardi-led and third-party research, consumer surveys, bartender interviews and TFL’s trend forecasting to uncover the forces shaping cocktail experiences, flavor innovation, and drinking culture in the year ahead. The Report also reveals the cocktails which are set to be the most popular in 2026 and trends for younger Legal Drinking Age (LDA) consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117678098/en/ The 7th annual Bacardi Cocktail Trends Report unveils what an
Arada to Acquire Majority Stake in £2.5bn Thameside West Development, Unlocking One of London’s Largest and Most Connected New Waterfront Neighbourhoods17.11.2025 12:58:00 CET | Press release
Arada, the UAE’s fastest-growing master developer, announces that it has agreed the acquisition of an 80% stake in Thameside West, a landmark waterfront mixed-use development located at the western end of London’s Royal Docks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117374964/en/ HH Sheikh Sultan bin Ahmed Al Qasimi, Chairman of Arada (centre) with members of the Arada and Keystone executive teams (Photo: AETOSWire) Master-planned by Foster + Partners, the vibrant new urban destination will deliver at least 5,000 homes, with half of the site dedicated to green space and a kilometre of active waterfront. Boasting unrivalled transport links, the integration of air, road, rail, river and tunnel links makes this one of the most connected sites in London. Spread over a 47-acre area – twice the size of the Hudson Yards mixed-use development in New York - Thameside West represents one of Europe’s largest and most strategi
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 12:00:00 CET | Press release
ZIIHERAplus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapyZIIHERA plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first interim analysisFirst Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
